Skip to main content
See every side of every news story
Get Started
SubscribeLogin
Published • loading... • Updated

Gut drug maker Ironwood expects $1.125–$1.175B 2026 LINZESS sales, advances weekly apraglutide for bowel failure

Summary by stocktitan.net
2025 revenue reached $296M with $138M adjusted EBITDA as guidance was achieved. Ironwood projects >$300M EBITDA for 2026 and plans Phase 3 apraglutide trial site launches in Q2.
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.Cross Cancel Icon

1 Articles

stocktitan.netstocktitan.net

Gut drug maker Ironwood expects $1.125–$1.175B 2026 LINZESS sales, advances weekly apraglutide for bowel failure

2025 revenue reached $296M with $138M adjusted EBITDA as guidance was achieved. Ironwood projects >$300M EBITDA for 2026 and plans Phase 3 apraglutide trial site launches in Q2.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

stocktitan.net broke the news in on Wednesday, February 25, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)
Blindspot Title And Logo
Stories disproportionately reported by the Left or the Right

Similar News Topics

Ironwood icon

Ironwood

News
Feed Dots Icon
For You
Search Icon
SearchBlindspot LogoBlindspotLocal